Glial biomarkers in human central nervous system disease

GLIA

Volumn 64, Issue 10, 2016, Pages 1755-1771

  Garden, Gwenn A ^a   Campbell, Brian M ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b LUNDBECK RESEARCH USA   (United States)

Author keywords

cerebrospinal fluid; inflammation; magnetic resonance imaging; neuroimaging; positron emission tomography

Indexed keywords

BIOLOGICAL MARKER; MYELIN;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM TUMOR; DEGENERATIVE DISEASE; DEPRESSION; GLIA; HUMAN; MACROGLIA; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NERVOUS SYSTEM INJURY; NEUROANATOMY; NEUROIMAGING; OLIGODENDROGLIA; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 84984992153     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22998     Document Type: Review

References (175)

1. Aalbers MW, Klinkenberg S, Rijkers K, Verschuure P, Kessels A, Aldenkamp A, Vles J, Majoie M. 2012. The effects of vagus nerve stimulation on pro- and anti-inflammatory cytokines in children with refractory epilepsy: An exploratory study. Neuroimmunomodulation 19:352–358.
2. Alsadany MA, Shehata HH, Mohamad MI, Mahfouz RG. 2013. Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer's disease. Am J Alzheimers Dis Other Demen 28:54–61.
3. Altar CA, Baudry M. 1990. Systemic injection of kainic acid: Gliosis in olfactory and limbic brain regions quantified with [3H]PK 11195 binding autoradiography. Exp Neurol 109:333–341.
4. Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw JJ. 2000. Microglia, amyloid and dementia in alzheimer disease. A correlative study. Neurobiol Aging 21:39–47.
5. Avram AV, Guidon A, Song AW. 2010. Myelin water weighted diffusion tensor imaging. NeuroImage 53:132–138.
6. Avsar T, Korkmaz D, Tutuncu M, Demirci NO, Saip S, Kamasak M, Siva A, Turanli ET. 2012. Protein biomarkers for multiple sclerosis: Semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis. Mult Scler 18:1081–1091.
7. Banati RB, Cagnin A, Brooks DJ, Gunn RN, Myers R, Jones T, Birch R, Anand P. 2001. Long-term trans-synaptic glial responses in the human thalamus after peripheral nerve injury. Neuroreport 12:3439–3442.
8. Banati RB, Myers R, Kreutzberg GW. 1997. PK ('peripheral benzodiazepine')–binding sites in the CNS indicate early and discrete brain lesions: Microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol 26:77–82.
9. Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zollner H, Reinacher-Schick A, Schmiegel W, Hahn W, Schroers R. 2011. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117:3140–3146.
10. Baron P, Bussini S, Cardin V, Corbo M, Conti G, Galimberti D, Scarpini E, Bresolin N, Wharton SB, Shaw PJ, et al. 2005. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve 32:541–544.
11. Bartosik-Psujek H, Stelmasiak Z. 2006. The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients. Clin Neurol Neurosurg 108:644–647.
12. Belzeaux R, Bergon A, Jeanjean V, Loriod B, Formisano-Treziny C, Verrier L, Loundou A, Baumstarck-Barrau K, Boyer L, Gall V, et al. 2012. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry 2:e185-
13. Benavides J, Quarteronet D, Imbault F, Malgouris C, Uzan A, Renault C, Dubroeucq MC, Gueremy C, Le Fur G. 1983. Labelling of “peripheral-type” benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: Kinetic studies and autoradiographic localization. J Neurochem 41:1744–1750.
14. Best MG, Sol N, Zijl S, Reijneveld JC, Wesseling P, Wurdinger T. 2015. Liquid biopsies in patients with diffuse glioma. Acta Neuropathol 129:849–865.
15. Bjork L, Leifsdottir K, Saha S, Herlenius E. 2013. PGE-metabolite levels in CSF correlate to HIE score and outcome after perinatal asphyxia. Acta Paediatr 102:1041–1047.
16. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. 2002a. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 72:237–241.
17. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M. 2002b. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 22:86–90.
18. Bornsen L, Khademi M, Olsson T, Sorensen PS, Sellebjerg F. 2011. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler 17:32–42.
19. Brites D, Vaz AR. 2014. Microglia centered pathogenesis in ALS: Insights in cell interconnectivity. Front Cell Neurosci 8:117-
20. Brundin L, Erhardt S, Bryleva EY, Achtyes ED, Postolache TT. 2015. The role of inflammation in suicidal behaviour. Acta Psychiatr Scand 132:192–203.
21. Burman J, Zetterberg H, Fransson M, Loskog AS, Raininko R, Fagius J. 2014. Assessing tissue damage in multiple sclerosis: A biomarker approach. Acta Neurol Scand 130:81–89.
22. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB. 2001a. In-vivo measurement of activated microglia in dementia. Lancet 358:461–467.
23. Cagnin A, Myers R, Gunn RN, Lawrence AD, Stevens T, Kreutzberg GW, Jones T, Banati RB. 2001b. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 124:2014–2027.
24. Cagnin A, Rossor M, Sampson EL, Mackinnon T, Banati RB. 2004. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol 56:894–897.
25. Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, Nordberg A. 2012. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 53:37–46.
26. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, et al. 2013. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 38:377–385.
27. Chiang SS, Riedel M, Schwarz M, Mueller N. 2013. Is T-helper type 2 shift schizophrenia-specific? Primary results from a comparison of related psychiatric disorders and healthy controls. Psychiatry Clin Neurosci 67:228–236.
28. Chio A, Pagani M, Agosta F, Calvo A, Cistaro A, Filippi M. 2014. Neuroimaging in amyotrophic lateral sclerosis: Insights into structural and functional changes. Lancet Neurol 13:1228–1240.
29. Choo IL, Carter SF, Scholl ML, Nordberg A. 2014. Astrocytosis measured by (1)(1)C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. Eur J Nucl Med Mol Imaging 41:2120–2126.
30. Cistaro A, Cuccurullo V, Quartuccio N, Pagani M, Valentini MC, Mansi L. 2014. Role of PET and SPECT in the study of amyotrophic lateral sclerosis. Biomed Res Int 2014:237437-
31. Clausen F, Marklund N, Lewen A, Enblad P, Basu S, Hillered L. 2012. Interstitial F(2)-isoprostane 8-iso-PGF(2alpha) as a biomarker of oxidative stress after severe human traumatic brain injury. J Neurotrauma 29:766–775.
32. Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, Nicolas G, Venel Y, Hommet C, Baulieu JL, et al. 2012. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One 7:e52941-
33. Corona AW, Huang Y, O'Connor JC, Dantzer R, Kelley KW, Popovich PG, Godbout JP. 2010. Fractalkine receptor (CX3CR1) deficiency sensitizes mice to the behavioral changes induced by lipopolysaccharide. J Neuroinflammation 7:93-
34. Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. 2009. MRI as an outcome in multiple sclerosis clinical trials. Neurology 72:705–711.
35. Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier A, Boulanghien J, Severac D, Buee L, Reme T, Lehmann S. 2015. Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach. Front Neurol 6:181-
36. Diniz BS, Teixeira AL, Talib L, Gattaz WF, Forlenza OV. 2010. Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients. Am J Geriatr Psychiatry 18:172–6.
37. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL. 2010. A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457.
38. Dzamba D, Harantova L, Butenko O, Anderova M. 2016. Glial cells - the key elements of Alzheimer s disease. Curr Alzheimer Res 13:1–18.
39. Eisenberger NI, Inagaki TK, Mashal NM, Irwin MR. 2010. Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav Immun 24:558–563.
40. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, Lundberg K, Postolache TT, Traskman-Bendz L, Guillemin GJ, et al. 2013. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 38:743–752.
41. Fischer L, Korfel A, Pfeiffer S, Kiewe P, Volk HD, Cakiroglu H, Widmann T, Thiel E. 2009. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res 15:5968–5973.
42. Foerch C, Otto B, Singer OC, Neumann-Haefelin T, Yan B, Berkefeld J, Steinmetz H, Sitzer M. 2004. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 35:2160–2164.
43. Fox MD, Raichle ME. 2007. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 8:700–711.
44. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. 1991. Blood-brain barrier transport of kynurenines: Implications for brain synthesis and metabolism. J Neurochem 56:2007–2017.
45. Furukawa T, Matsui N, Fujita K, Nodera H, Shimizu F, Miyamoto K, Takahashi Y, Kanda T, Kusunoki S, Izumi Y, et al. 2015. CSF cytokine profile distinguishes multifocal motor neuropathy from progressive muscular atrophy. Neurol Neuroimmunol Neuroinflamm 2:e138-
46. Gabbay V, Ely BA, Babb J, Liebes L. 2012. The possible role of the kynurenine pathway in anhedonia in adolescents. J Neural Transm (Vienna) 119:253–260.
47. Gabbay V, Klein RG, Katz Y, Mendoza S, Guttman LE, Alonso CM, Babb JS, Hirsch GS, Liebes L. 2010. The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry 51:935–943.
48. Galetta KM, Balcer LJ. 2013. Measures of visual pathway structure and function in MS: Clinical usefulness and role for MS trials. Mult Scler Relat Disord 2:172–182.
49. Gehlert DR, Stephenson DT, Schober DA, Rash K, Clemens JA. 1997. Increased expression of peripheral benzodiazepine receptors in the facial nucleus following motor neuron axotomy. Neurochem Int 31:705–713.
50. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. 2006. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21:404–412.
51. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, et al. 2010. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330:841–845.
52. Gitter BD, Cox LM, Rydel RE, May PC. 1995. Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells. Proc Natl Acad Sci U S A 92:10738–10741.
53. Goerres GW, Revesz T, Duncan J, Banati RB. 2001. Imaging cerebral vasculitis in refractory epilepsy using [(11)C](R)-PK11195 positron emission tomography. AJR Am J Roentgenol 176:1016–1018.
54. Goudriaan A, de Leeuw C, Ripke S, Hultman CM, Sklar P, Sullivan PF, Smit AB, Posthuma D, Verheijen MH. 2014. Specific glial functions contribute to schizophrenia susceptibility. Schizophr Bull 40:925–935.
55. Greene DN, Schmidt RL, Wilson AR, Freedman MS, Grenache DG. 2012. Cerebrospinal Fluid Myelin Basic Protein Is Frequently Ordered but Has Little Value. A Test Utilization Study. Am J Clin Pathol 138:262–272.
56. Guest FL, Guest PC, Martins-de-Souza D. 2016. The emergence of point-of-care blood-based biomarker testing for psychiatric disorders: enabling personalized medicine. Biomark Med 10:431–443.
57. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. 2005. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 31:395–404.
58. Gulyas B, Pavlova E, Kasa P, Gulya K, Bakota L, Varszegi S, Keller E, Horvath MC, Nag S, Hermecz I, et al. 2011. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int 58:60–68.
59. Harrison PJ, Weinberger DR. 2005. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 10:40–68; image 5.
60. Herrmann M, Curio N, Jost S, Grubich C, Ebert AD, Fork ML, Synowitz H. 2001. Release of biochemical markers of damage to neuronal and glial brain tissue is associated with short and long term neuropsychological outcome after traumatic brain injury. J Neurol Neurosurg Psychiatry 70:95–100.
61. Hjalmarsson C, Bjerke M, Andersson B, Blennow K, Zetterberg H, Aberg ND, Olsson B, Eckerstrom C, Bokemark L, Wallin A. 2014a. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J Cent Nerv Syst Dis 6:51–58.
62. Howren MB, Lamkin DM, Suls J. 2009. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71:171–186.
63. Hu Y, Yu SY, Zuo LJ, Cao CJ, Wang F, Chen ZJ, Du Y, Lian TH, Wang YJ, Chan P, et al. 2015. Parkinson disease with REM sleep behavior disorder: Features, alpha-synuclein, and inflammation. Neurology 84:888–894.
64. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. 2003. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 106:518–526.
65. Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, Arai H, Furukawa K. 2015. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem 136:258–261.
66. Italiani P, Carlesi C, Giungato P, Puxeddu I, Borroni B, Bossu P, Migliorini P, Siciliano G, Boraschi D. 2014. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J Neuroinflammation 11:94-
67. Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR, Group Nr-PSS. 2006. Association of serial biochemical markers with acute ischemic stroke: The National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 37:2508–2513.
68. Jazayeri S, Keshavarz SA, Tehrani-Doost M, Djalali M, Hosseini M, Amini H, Chamari M, Djazayery A. 2010. Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res 178:112–115.
69. Jebelli J, Su W, Hopkins S, Pocock J, Garden GA. 2015. Glia: Guardians, gluttons, or guides for the maintenance of neuronal connectivity? Ann N Y Acad Sci 1351:1–10.
70. Johansson A, Engler H, Blomquist G, Scott B, Wall A, Aquilonius SM, Langstrom B, Askmark H. 2007. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci 255:17–22.
71. Kahl KG, Bens S, Ziegler K, Rudolf S, Dibbelt L, Kordon A, Schweiger U. 2006. Cortisol, the cortisol-dehydroepiandrosterone ratio, and pro-inflammatory cytokines in patients with current major depressive disorder comorbid with borderline personality disorder. Biol Psychiatry 59:667–671.
72. Kastelein JJ, Wiegman A, de Groot E. 2003. Surrogate markers of atherosclerosis: Impact of statins. Atheroscler Suppl 4:31–36.
73. Kegel ME, Bhat M, Skogh E, Samuelsson M, Lundberg K, Dahl ML, Sellgren C, Schwieler L, Engberg G, Schuppe-Koistinen I, et al. 2014. Imbalanced kynurenine pathway in schizophrenia. Int J Tryptophan Res 7:15–22.
74. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. 2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617–627.
75. Kim TS, Lim HK, Lee JY, Kim DJ, Park S, Lee C, Lee CU. 2008. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 436:196–200.
76. Kivisakk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, Sevdalinova V, Quintana F, Chitnis T, Weiner HL, et al. 2014. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: Relevance for biomarker development. Mult Scler 20:438–444.
77. Kozak R, Campbell BM, Strick CA, Horner W, Hoffmann WE, Kiss T, Chapin DS, McGinnis D, Abbott AL, Roberts BM, et al. 2014. Reduction of brain kynurenic acid improves cognitive function. J Neurosci 34:10592–10602.
78. Kros JM, Mustafa DM, Dekker LJ, Sillevis Smitt PA, Luider TM, Zheng PP. 2015. Circulating glioma biomarkers. Neuro Oncol 17:343–360.
79. Kuhle J, Lindberg RL, Regeniter A, Mehling M, Steck AJ, Kappos L, Czaplinski A. 2009. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol 16:771–774.
80. Kumlien E, Bergstrom M, Lilja A, Andersson J, Szekeres V, Westerberg CE, Westerberg G, Antoni G, Langstrom B. 1995. Positron emission tomography with [11C]deuterium-deprenyl in temporal lobe epilepsy. Epilepsia 36:712–721.
81. Kwon BK, Stammers AM, Belanger LM, Bernardo A, Chan D, Bishop CM, Slobogean GP, Zhang H, Umedaly H, Giffin M, et al. 2010. Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J Neurotrauma 27:669–682.
82. Lasiene J, Yamanaka K. 2011. Glial cells in amyotrophic lateral sclerosis. Neurol Res Int 2011:718987.
83. Laule C, Vavasour I, Kolind S, Li DB, Traboulsee T, Moore GRW, MacKay A. 2007. Magnetic resonance imaging of myelin. Neurotherapeutics 4:460–484.
84. Le Fur G, Vaucher N, Perrier ML, Flamier A, Benavides J, Renault C, Dubroeucq MC, Gueremy C, Uzan A. 1983. Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies. Life Sci 33:449–457.
85. Letendre SL, Zheng JC, Kaul M, Yiannoutsos CT, Ellis RJ, Taylor MJ, Marquie-Beck J, Navia B, Consortium HIVN. 2011. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol 17:63–69.
86. Lewis DA, Hashimoto T, Volk DW. 2005. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312–324.
87. Leypoldt F, Hoftberger R, Titulaer MJ, Armangue T, Gresa-Arribas N, Jahn H, Rostasy K, Schlumberger W, Meyer T, Wandinger KP, et al. 2015. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: A potential biomarker of treatment response. JAMA Neurol 72:180–186.
88. Lichtblau N, Schmidt FM, Schumann R, Kirkby KC, Himmerich H. 2013. Cytokines as biomarkers in depressive disorder: Current standing and prospects. Int Rev Psychiatry 25:592–603.
89. Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, Samuelsson M, Erhardt S. 2012. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 38:426–432.
90. Liu C, Cui G, Zhu M, Kang X, Guo H. 2014. Neuroinflammation in Alzheimer's disease: Chemokines produced by astrocytes and chemokine receptors. Int J Clin Exp Pathol 7:8342–8355.
91. Mackay GM, Forrest CM, Christofides J, Bridel MA, Mitchell S, Cowlard R, Stone TW, Darlington LG. 2009. Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clin Exp Pharmacol Physiol 36:425–435.
92. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. 2003. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 61:1720–1725.
93. Mao X, Sun Y, Tang J. 2014. Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma. Neurol Sci 35:233–238.
94. Marrer E, Dieterle F. 2007. Promises of biomarkers in drug development–a reality check. Chem Biol Drug Des 69:381–394.
95. Martinez MA, Olsson B, Bau L, Matas E, Cobo Calvo A, Andreasson U, Blennow K, Romero-Pinel L, Martinez-Yelamos S, Zetterberg H. 2015. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler 21:550–561.
96. Matthews PM, Datta G. 2015. Positron-emission tomography molecular imaging of glia and myelin in drug discovery for multiple sclerosis. Expert Opin Drug Discov 10:557–570.
97. McGeer PL, Itagaki S, Boyes BE, McGeer EG. 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285–1291.
98. Mehla R, Bivalkar-Mehla S, Nagarkatti M, Chauhan A. 2012. Programming of neurotoxic cofactor CXCL-10 in HIV-1-associated dementia: Abrogation of CXCL-10-induced neuro-glial toxicity in vitro by PKC activator. J Neuroinflammation 9:239-
99. Mellergard J, Edstrom M, Vrethem M, Ernerudh J, Dahle C. 2010. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 16:208–217.
100. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. 2011. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671.
101. Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. 2009. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: An astrocytic damage marker. J Neurol Neurosurg Psychiatry 80:575–577.
102. Modvig S, Degn M, Horwitz H, Cramer SP, Larsson HBW, Wanscher B, Sellebjerg F, Frederiksen JL. 2013. Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis. PLoS One 8:e77163-
103. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T. 1994a. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147–150.
104. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. 1994b. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165:208–210.
105. Mondello S, Jeromin A, Buki A, Bullock R, Czeiter E, Kovacs N, Barzo P, Schmid K, Tortella F, Wang KK, et al. 2012. Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. J Neurotrauma 29:1096–1104.
106. Mondello S, Papa L, Buki A, Bullock MR, Czeiter E, Tortella FC, Wang KK, Hayes RL. 2011. Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: A case control study. Crit Care 15:R156-
107. Monji A, Kato T, Kanba S. 2009. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 63:257–265.
108. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD. 2012. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17:419–424.
109. Muller N, Myint AM, Schwarz MJ. 2012. Inflammation in schizophrenia. Adv Protein Chem Struct Biol 88:49–68.
110. Nag S, Fazio P, Lehmann L, Kettschau G, Heinrich T, Thiele A, Svedberg M, Amini N, Leesch S, Catafau A, et al. 2015. In Vivo/In Vitro Characterisation of a Novel MAO-B Inhibitor Radioligand, Fluorine-18 Labeled Deuterated Fluorodeprenyl (18F-Fluorodeprenyl-D2). J Nucl Med 57:315–320.
111. Nagatsu T, Mogi M, Ichinose H, Togari A. 2000. Cytokines in Parkinson's disease. J Neural Transm Suppl 143–151.
112. Nakamizo S, Sasayama T, Shinohara M, Irino Y, Nishiumi S, Nishihara M, Tanaka H, Tanaka K, Mizukawa K, Itoh T, et al. 2013. GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. J Neurooncol 113:65–74.
113. Niranjan R. 2013. Molecular basis of etiological implications in Alzheimer's disease: Focus on neuroinflammation. Mol Neurobiol 48:412–428.
114. O'Brien ER, Kersemans V, Tredwell M, Checa B, Serres S, Soto MS, Gouverneur V, Leppert D, Anthony DC, Sibson NR. 2014. Glial activation in the early stages of brain metastasis: TSPO as a diagnostic biomarker. J Nucl Med 55:275–280.
115. O'Connor JC, Lawson MA, Andre C, Briley EM, Szegedi SS, Lestage J, Castanon N, Herkenham M, Dantzer R, Kelley KW. 2009. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 182:3202–3212.
116. Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, Saso S. 1992. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42:1702–1706.
117. Otto M, Bahn E, Wiltfang J, Boekhoff I, Beuche W. 1998. Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis. Neurosci Lett 240:171–173.
118. Pappata S, Levasseur M, Gunn RN, Myers R, Crouzel C, Syrota A, Jones T, Kreutzberg GW, Banati RB. 2000. Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195. Neurology 55:1052–1054.
119. Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. 2004. GFAP versus S100B in serum after traumatic brain injury: Relationship to brain damage and outcome. J Neurotrauma 21:1553–1561.
120. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH, Cuzner ML, Polman CH, Uitdehaag BM, Thompson EJ, et al. 2002. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 125:1462–1473.
121. Petzold A, Michel P, Stock M, Schluep M. 2008. Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcome. J Stroke Cerebrovasc Dis 17:196–203.
122. Philips T, Robberecht W. 2011. Neuroinflammation in amyotrophic lateral sclerosis: Role of glial activation in motor neuron disease. Lancet Neurol 10:253–263.
123. Plog BA, Dashnaw ML, Hitomi E, Peng W, Liao Y, Lou N, Deane R, Nedergaard M. 2015. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J Neurosci 35:518–526.
124. Qu S, Guan J, Liu Y. 2015. Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. J Neurol Sci 348:181–187.
125. Quintana FJ, Farez MF, Izquierdo G, Lucas M, Cohen IR, Weiner HL. 2012. Antigen microarrays identify CNS-produced autoantibodies in RRMS. Neurology 78:532–539.
126. Radford RA, Morsch M, Rayner SL, Cole NJ, Pountney DL, Chung RS. 2015. The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia. Front Cell Neurosci 9:414-
127. Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ. 2009. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One 4:e6344-
128. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. 2013. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31–41.
129. Rentzos M, Rombos A, Nikolaou C, Zoga M, Zouvelou V, Dimitrakopoulos A, Alexakis T, Tsoutsou A, Samakovli A, Michalopoulou M, et al. 2010. Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: A reflection of Th17 cells activation? Acta Neurol Scand 122:425–429.
130. Rizzi L, Roriz-Cruz M. 2016. Cerebrospinal fluid inflammatory markers in amnestic mild cognitive impairment. Geriatr Gerontol Int. Epub ahead of print
131. Romme Christensen J, Ratzer R, Bornsen L, Lyksborg M, Garde E, Dyrby TB, Siebner HR, Sorensen PS, Sellebjerg F. 2014. Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial. Neurology 82:1499–1507.
132. Saresella M, Piancone F, Tortorella P, Marventano I, Gatti A, Caputo D, Lunetta C, Corbo M, Rovaris M, Clerici M. 2013. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clin Immunol 148:79–88.
133. Sasagawa Y, Akai T, Tachibana O, Iizuka H. 2015. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system. J Neurooncol 121:177–183.
134. Savman K, Heyes MP, Svedin P, Karlsson A. 2013. Microglia/macrophage-derived inflammatory mediators galectin-3 and quinolinic acid are elevated in cerebrospinal fluid from newborn infants after birth asphyxia. Transl Stroke Res 4:228–235.
135. Schmidt HD, Shelton RC, Duman RS. 2011. Functional biomarkers of depression: Diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36:2375–2394.
136. Scholl M, Carter SF, Westman E, Rodriguez-Vieitez E, Almkvist O, Thordardottir S, Wall A, Graff C, Langstrom B, Nordberg A. 2015. Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. Sci Rep 5:16404-
137. Schwarz MJ, Muller N, Riedel M, Ackenheil M. 2001. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 56:483–486.
138. Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, Finn A, Bhat M, Samuelsson M, Lundberg K, et al. 2015. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia–significance for activation of the kynurenine pathway. J Psychiatry Neurosci 40:126–133.
139. Scott BJ, Douglas VC, Tihan T, Rubenstein JL, Josephson SA. 2013. A systematic approach to the diagnosis of suspected central nervous system lymphoma. JAMA Neurol 70:311–319.
140. Semple BD, Bye N, Rancan M, Ziebell JM, Morganti-Kossmann MC. 2010. Role of CCL2 (MCP-1) in traumatic brain injury (TBI): Evidence from severe TBI patients and CCL2-/- mice. J Cereb Blood Flow Metab 30:769–782.
141. Sheline YI, Raichle ME. 2013. Resting state functional connectivity in preclinical Alzheimer's disease. Biol Psychiatry 74:340–347.
142. Smith RS, Maes M. 1995. The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence. Med Hypotheses 45:135–141.
143. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, Capurso SA, Pietrarossa G, Santamato V, Capurso A, et al. 2006. Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta 364:91–112.
144. Spader HS, Ellermeier A, O'Muircheartaigh J, Dean DC III, Dirks H, Boxerman JL, Cosgrove GR, Deoni SC. 2013. Advances in myelin imaging with potential clinical application to pediatric imaging. Neurosurg Focus 34:E9-
145. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. 2005. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128:1016–1025.
146. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, et al. 2011. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 8:94-
147. Stephenson DT, Schober DA, Smalstig EB, Mincy RE, Gehlert DR, Clemens JA. 1995. Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J Neurosci 15:5263–5274.
148. Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Muigg A, Kiechl S, Schmutzhard E, Maier H, Felber S, Schumacher P, et al. 2000. Vascular endothelial growth factor in CSF: A biological marker for carcinomatous meningitis. Neurology 54:1670–1676.
149. Su E, Bell MJ, Kochanek PM, Wisniewski SR, Bayır H, Clark RSB, Adelson PD, Tyler-Kabara EC, Janesko-Feldman KL, Berger RP. 2012. Increased CSF Concentrations of Myelin Basic Protein After TBI in Infants and Children: Absence of Significant Effect of Therapeutic Hypothermia. Neurocrit Care 17:10–1007. /s12028-012-9767-0.
150. Su Z, Roncaroli F, Durrenberger PF, Coope DJ, Karabatsou K, Hinz R, Thompson G, Turkheimer FE, Janczar K, Du Plessis D, et al. 2015. The 18-kDa mitochondrial translocator protein in human gliomas: an 11C-(R)PK11195 PET imaging and neuropathology study. J Nucl Med 56:512–517.
151. Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA, Mann JJ, Postolache TT. 2011. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun 25:1272–1278.
152. Sussmuth SD, Tumani H, Ecker D, Ludolph AC. 2003. Amyotrophic lateral sclerosis: Disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett 353:57–60.
153. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. 2010. Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study. Neurology 75:208–216.
154. Tang P, Chong L, Li X, Liu Y, Liu P, Hou C, Li R. 2014. Correlation between serum RANTES levels and the severity of Parkinson's disease. Oxid Med Cell Longev 2014:208408-
155. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, O'Brien JT. 2005. Increase in interleukin-1beta in late-life depression. Am J Psychiatry 162:175–177.
156. Thrane AS, Rangroo Thrane V, Nedergaard M. 2014. Drowning stars: Reassessing the role of astrocytes in brain edema. Trends Neurosci 37:620–628.
157. Tumilson CA, Lea RW, Alder JE, Shaw L. 2014. Circulating microRNA biomarkers for glioma and predicting response to therapy. Mol Neurobiol 50:545–558.
158. Turetsky A, Lee K, Song J, Giedt RJ, Kim E, Kovach AE, Hochberg EP, Castro CM, Lee H, Weissleder R. 2015. On chip analysis of CNS lymphoma in cerebrospinal fluid. Theranostics 5:796–804.
159. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ, Leigh PN, Banati RB. 2004. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 15:601–609.
160. Verkhratsky A, Nedergaard M, Hertz L. 2015. Why are astrocytes important? Neurochem Res 40:389–401.
161. Verkhratsky A, Parpura V, Pekna M, Pekny M, Sofroniew M. 2014. Glia in the pathogenesis of neurodegenerative diseases. Biochem Soc Trans 42:1291–1301.
162. Viaccoz A, Ducray F, Tholance Y, Barcelos GK, Thomas-Maisonneuve L, Ghesquieres H, Meyronet D, Quadrio I, Cartalat-Carel S, Louis-Tisserand G, et al. 2015. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. Neuro Oncol 17:1497–1503.
163. Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, Choi DK, Tieu K, Przedborski S. 2001. The role of glial cells in Parkinson's disease. Curr Opin Neurol 14:483–489.
164. Vincze O, Olah J, Zadori D, Klivenyi P, Vecsei L, Ovadi J. 2011. A new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosis. Biochem Biophys Res Commun 409:137–141.
165. Wang KK, Yang Z, Yue JK, Zhang Z, Winkler EA, Puccio A, Diaz-Arrastia R, Lingsma H, Yuh EL, Mukherjee P, et al. 2015. Plasma Anti-Glial Fibrillary Acidic Protein (GFAP) Autoantibody Levels During the Acute and Chronic Phases of Traumatic Brain Injury - A TRACK-TBI Pilot Study. J Neurotrauma. Epub ahead of print
166. Wei D, Wan Q, Li L, Jin H, Liu Y, Wang Y, Zhang G. 2015. MicroRNAs as Potential Biomarkers for Diagnosing Cancers of Central Nervous System: A Meta-analysis. Mol Neurobiol 51:1452–1461.
167. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. 2012. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One 7:e30525-
168. Widner B, Leblhuber F, Fuchs D. 2002. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J Neural Transm (Vienna) 109:181–189.
169. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. 1999. Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol 467:133–138.
170. Xiao M, Hu G. 2014. Involvement of aquaporin 4 in astrocyte function and neuropsychiatric disorders. CNS Neurosci Ther 20:385–390.
171. Yang Z, Wang KKW. 2015. Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci 38:364–374.
172. Yu SY, Zuo LJ, Wang F, Chen ZJ, Hu Y, Wang YJ, Wang XM, Zhang W. 2014. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: A cross-sectional study. BMC Neurol 14:113-
173. Zhang R, Miller RG, Madison C, Jin X, Honrada R, Harris W, Katz J, Forshew DA, McGrath MS. 2013. Systemic immune system alterations in early stages of Alzheimer's disease. J Neuroimmunol 256:38–42.
174. Zhang Z, Zoltewicz JS, Mondello S, Newsom KJ, Yang Z, Yang B, Kobeissy F, Guingab J, Glushakova O, Robicsek S, et al. 2014. Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products. PLoS One 9:e92698-
175. Zinger A, Barcia C, Herrero MT, Guillemin GJ. 2011. The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease. Parkinsons Dis 2011:716859-